Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Outpatient Oncology Infusion Market Revenue Growth Supported By A CAGR Of 20.21% Through 2030
The market for outpatient oncology infusions has experienced robust expansion lately, with projections indicating continued growth from $14.02 billion in 2025 to $15.12 billion in 2026, reflecting a compound annual growth rate of 7.8%. This upswing in the historical period is largely due to a rise in cancer incidence, the broadening of outpatient oncology facilities, the increasing use of infusion therapies, enhanced survival rates necessitating sustained care, and the accessibility of sophisticated infusion equipment.
The outpatient oncology infusion sector is poised for considerable expansion over the upcoming years, projecting a market value of $20.21 billion by 2030, driven by a compound annual growth rate of 7.5%. This anticipated growth stems from several key factors: a heightened demand for personalized or precision oncology therapies, increased financial commitments towards outpatient infusion facilities, advancements in home healthcare infusion technology, a greater emphasis on economical cancer treatment strategies, and the growing integration of digital tools for monitoring oncological conditions. Furthermore, the forecast period is characterized by significant market shifts, including a pronounced movement towards cancer treatments administered in outpatient settings, wider adoption of targeted therapies and immunotherapies, increased utilization of sophisticated smart infusion pumps, the continued development of ambulatory infusion centers, and a heightened dedication to prioritizing patient needs within cancer care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25861&type=smp
Outpatient Oncology Infusion Market Expansion Drivers: What Is Shaping Future Growth?
The expanding incidence of cancer diagnoses is anticipated to be a key catalyst for the advancement of the outpatient oncology infusion market in the future. Cancer, characterized by the uncontrolled proliferation of aberrant cells with the capacity to infiltrate adjacent tissues and metastasize to distant sites, presents a complex health challenge. This rising cancer burden is largely attributable to global demographic shifts towards older populations, as the propensity for cancer development escalates markedly with advancing age. Outpatient oncology infusion services offer a means of delivering cancer therapies, including chemotherapy, immunotherapy, and targeted treatments, within a non-inpatient healthcare environment, thereby enabling patients to undergo treatment while continuing with their regular lives. As an illustration, Macmillan Cancer Support, a charitable organization in the United Kingdom offering comprehensive assistance for those impacted by cancer, estimated in April 2024 that the cancer population in the UK is projected to surpass 3 million currently, with projections indicating 3.5 million by 2025, 4 million by 2030, and ultimately 5.3 million by 2040. Consequently, the growing number of cancer cases is directly fueling the expansion of the market for outpatient oncology infusion.
Outpatient Oncology Infusion Market Segment Performance And Strategic Opportunities
The outpatient oncology infusion market covered in this report is segmented –
1) By Product: Infusion Pumps, Intravenous Sets, Intravenous Cannulas, Needleless Connectors
2) By Therapy: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy
3) By Application: Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer, Other Cancers
4) By End-User: Hospitals, Outpatient Clinics, Home Care Settings
Subsegments:
1) By Infusion Pumps: Volumetric Infusion Pumps, Syringe Infusion Pumps, Elastomeric Infusion Pumps, Ambulatory Infusion Pumps, Smart Infusion Pumps
2) By Intravenous Sets: Vented IV Sets, Non-Vented IV Sets, Gravity IV Sets, Pump-Compatible IV Sets, Filtered IV Sets
3) By Intravenous Cannulas: Peripheral IV Cannulas, Central IV Cannulas, Winged IV Cannulas (Butterfly), Closed IV Cannulas, Safety IV Cannulas
4) By Needleless Connectors: Positive Displacement Connectors, Negative Displacement Connectors, Neutral Displacement Connectors, Closed System Transfer Devices (CSTDs), Anti-Reflux Connectors
Outpatient Oncology Infusion Market Strategic Trends: What Is Defining The Next Phase Of Growth?
In the sphere of outpatient oncology infusion, leading enterprises are prioritizing innovation within infusion technology, specifically developing advanced smart infusion pumps. These cutting-edge devices aim to elevate patient safety and optimize the administration of chemotherapy. Such next-generation smart infusion pumps are characterized by their digital connectivity and sophisticated software designed to reduce dosage errors. They also feature comprehensive drug databases and real-time communication capabilities, all contributing to error reduction and the standardization of cancer treatment protocols. Illustrating this trend, Baxter International Inc., a prominent American medical technology firm, secured FDA 510(k) approval in April 2024 for its Novum IQ large-volume infusion pump, thereby enabling its availability for ordering within the United States. This integrated hardware and software solution is engineered to deliver precise, large-volume infusions, incorporating built-in safety mechanisms, strict adherence to drug libraries, and the capacity for remote oversight. Baxter emphasizes the pump’s sophisticated safety framework, enhanced user-friendliness, and seamless integration with its existing infusion product range. The Novum IQ pump is particularly well-suited for outpatient oncology infusion facilities, outpatient clinics, and hospitals, promising advantages like heightened dosing precision, more efficient nursing processes, and a reduction in treatment interruptions or negative patient outcomes during chemotherapy sessions.
Outpatient Oncology Infusion Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the outpatient oncology infusion market are Medtronic plc, Becton Dickinson and Company, Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Nipro Corporation, Smiths Medical Inc., ICU Medical Inc., B. Braun Melsungen AG, InfuSystem Holdings Inc., BPL Medical Technologies Private Limited, Angiplast Private Limited, Bio-Med Healthcare Products Private Limited, Lars Medicare Private Limited, Micrel Medical Devices S.A., AKAS Infusions Private Limited, Mais India Medical Devices Private Limited, Wellead Medical Co. Ltd., AdvaCare Pharma USA LLC, Polymed Medical Devices Private Limited.
Access The Complete Outpatient Oncology Infusion Market Report:
https://www.thebusinessresearchcompany.com/report/outpatient-oncology-infusion-global-market-report
Outpatient Oncology Infusion Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the outpatient oncology infusion market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the outpatient oncology infusion market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
